The first hybrid closed-loop (HCL) system, with automated insulin delivery but still requiring user inputs, was approved for the treatment of Type 1 Diabetes (T1D) by the U.S. Food and Drug Administration in September 2016. This evidence concerns the gene INS and type 1 diabetes mellitus.